Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bad Things Come In Threes At Viatris As Firm Issues Another Labelling Recall

Viatris Recalls Third Insulin Product This Year Over Missing Labels

Executive Summary

Viatris has recalled a batch of its unbranded insulin glargine injector pens after a manufacturing error meant some pens might be missing labels. It is the third time this year the firm has had to recall an insulin product due to a labelling error.

You may also be interested in...



Labels The Issue For Viatris Again As It Recalls Insulin Glargine Biosimilar

A further voluntary recall for Viatris’ insulin glargine biosimilar, this time for one of its recently launched interchangeable products, because of missing labels may draw unwanted interest from the US FDA, a leading analyst has warned.

Viatris Recalls Semglee Batch Citing Missing Labels

Viatris has voluntarily recalled one batch of its Semglee (insulin glargine) pre-filled pens due to the potential for the label to be missing on some pre-filled pens within a labelled carton. The company said that it will arrange for the return of all recalled products. 

US Patients Continue To Overpay For Off-Patent Drugs Despite $373bn In Savings

The US Association for Accessible Medicines’ annual report into generic and biosimilar savings has documented another year of increased cost savings thanks to off-patent drugs, but says some patients are still overpaying for their generic medicines. 

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel